Galmed Pharmaceuticals Ltd. (GLMD)
4.05
-0.26
(-5.92%)
USD |
NASDAQ |
Aug 24, 16:00
4.02
-0.03
(-0.74%)
After-Hours: 20:00
Galmed Pharmaceuticals Enterprise Value : -12.23M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -12.23M |
| August 21, 2026 | -12.02M |
| August 20, 2026 | -11.81M |
| August 19, 2026 | -11.64M |
| August 18, 2026 | -11.88M |
| August 17, 2026 | -12.19M |
| August 14, 2026 | -12.12M |
| August 13, 2026 | -12.07M |
| August 12, 2026 | -11.88M |
| August 11, 2026 | -11.90M |
| August 10, 2026 | -11.66M |
| August 07, 2026 | -11.60M |
| August 06, 2026 | -11.62M |
| August 05, 2026 | -11.75M |
| August 04, 2026 | -11.78M |
| August 03, 2026 | -11.72M |
| July 31, 2026 | -11.48M |
| July 30, 2026 | -11.62M |
| July 29, 2026 | -11.88M |
| July 28, 2026 | -12.05M |
| July 27, 2026 | -12.10M |
| July 24, 2026 | -12.19M |
| July 23, 2026 | -11.93M |
| July 22, 2026 | -12.24M |
| July 21, 2026 | -12.15M |
| Date | Value |
|---|---|
| July 20, 2026 | -12.18M |
| July 17, 2026 | -11.97M |
| July 16, 2026 | -11.95M |
| July 15, 2026 | -12.19M |
| July 14, 2026 | -12.20M |
| July 13, 2026 | -12.03M |
| July 10, 2026 | -11.88M |
| July 09, 2026 | -11.81M |
| July 08, 2026 | -11.81M |
| July 07, 2026 | -11.82M |
| July 06, 2026 | -11.90M |
| July 02, 2026 | -11.81M |
| July 01, 2026 | -11.30M |
| June 30, 2026 | -11.90M |
| June 29, 2026 | -11.81M |
| June 26, 2026 | -11.79M |
| June 25, 2026 | -11.79M |
| June 24, 2026 | -11.70M |
| June 23, 2026 | -11.80M |
| June 22, 2026 | -11.85M |
| June 18, 2026 | -11.75M |
| June 17, 2026 | -11.61M |
| June 16, 2026 | -11.59M |
| June 15, 2026 | -11.51M |
| June 12, 2026 | -11.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioLineRx Ltd. | 8.933M |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 428.03M |
| Can-Fite BioPharma Ltd. | -4.492M |
| Revium Recovery, Inc. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.91M |
| Total Expenses (Quarterly) | 1.91M |
| EPS Diluted (Quarterly) | -2.318 |
| Earnings Yield | -395.1% |
| Normalized Earnings Yield | -336.04 |